Toll-like receptor 9 agonist inhibits ERα-mediated transactivation by activating NF-κB in breast cancer cell lines

JIANMING QIU[1,2], XIAOJIAN WANG[1], XINHAI GUO[2], CHENYIN ZHAO[2], XUHUI WU[2] and YONGKUI ZHANG[2]

[1]Institute of Immunology, Zhejiang University School of Medicine, Hangzhou;
[2]The First People's Hospital of Zhoushan, Zhoushan, P.R. China

Abstract. Primarily, Toll-like receptor 9 (TLR9) is a specific receptor for microbial DNA in human immune cells. TLR9 has been found to be a promising target in tumor immunotherapy but the direct effect of its activation on tumor cells remains unknown. In this study, we examined the effect of TLR9 ligation on estrogen receptor α (ERα)-mediated transactivation of breast cancer. Luciferase report gene assays, RNA interference of TLR9 and Chromatin immunoprecipitation were performed to measure the effect of TLR9 ligation on ERα-mediated transactivity of T47D and MCF-7 cells. Bromodeoxyuridine incorporation assay was used to examine the effect of TLR9 ligation on estrogen (E2)-induced proliferation of breast cancer cells. We also investigated the mechanism for the effect of TLR9 ligation on ERα-mediated transactivity. We found that ERα-mediated transcription via estrogen response element of human breast cancer cells line T47D was significantly suppressed when treated with 17ß-estradiol in combination with TLR9 agonist CpG oligonucleotides and this effect of CpG was dependent on TLR9. Furthermore, nuclear factor κB (NF-κB) inhibitor BAY 11-7082 could abolish the inhibitory effect of CpG oligonucleotides on ERα-mediated transactivation. We also confirmed the effect of CpG oligonucleotides on ERα-mediated transactivation in the breast cancer cell line MCF-7 forced to stably overexpress TLR9. Finally, we observed that CpG oligonucleotides were also able to inhibit estrogen-induced proliferation of breast cancer cells as a consequence of decreased ERα-mediated transactivation. Taken together, our data suggest that TLR9 signal pathway, by activating NF-κB, negatively regulates ERα-mediated transactivation of breast cancer. Thus, TLR9 agonist inhibits the proliferation of breast cancer cells in response to estrogen.

Introduction

Toll-like receptors (TLRs) are evolutionarily well-conserved transmembrane proteins that are present in almost all multi-cellular organisms and recognize patterns specific for microbial components (1). TLR9, specifically recognizing unmethylated CpG oligonucleotides in vertebrates, is localized at endoplasmic reticulum, from where it is translocated to the endosomal/lysosomal compartment for ligand recognition (2). On ligand binding, TLRs and their associated adaptors, such as MyD88 and TRIF, recruit intracellular signaling mediators that activate transcription factors, such as nuclear factor κB (NF-κB). The outcome of TLR activation is an immune reaction characterized by increased production of various proinflammatory cytokines and interleukins (3).

Estrogen is involved in the growth and differentiation of diverse tissues (4). As a pontent mitogen, it accounts for at least 40% of female breast cancer (5). Effects of estrogen are largely exerted through the activation of estrogen receptor α (ERα), the classic estrogen receptor that belongs to the steroid/thyroid nuclear receptor superfamily of ligand regulated transcription factors (6). Binding of estrogen to ERα leads to transcription of a wide range of genes which stimulate proliferation of mammary cells and the increase in cell division and DNA synthesis elevates the risk for replication errors, which may result in the acquisition of detrimental mutations that disrupt normal cellular processes such as apoptosis, cellular proliferation, or DNA repair (7). Because of the pivotal role of the ERα axis in breast cancer development, targeting ERα or its ligands is a major strategy for breast cancer treatment (8).

Several previous studies have suggested that TLR9 is highly expressed in breast cancer cells (9,10). We wondered whether TLR9 has a role in regulating ERα-mediated transactivation of breast cancer directly. In this study, we demonstrated, for the first time, that TLR9 ligation can significantly inhibit response of breast cancer to estrogen by down-regulating ERα-mediated transactivation.

Materials and methods

Reagents and cell culture. 17ß-estradiol and NF-κB inhibitor BAY 11-7082 were purchased from Calbiochem (La Jolla, CA). Human-specific TLR9 agonist CpG oligonucleotides (type C: 5-tcgtcgtcgttcgaacgacgttgat-3) and non-CpG control (type C control: 5-tgctgctgcttgcaagcagcttgat-3) was purchased from InVivoGen (San Diego, CA). T47D and MCF-7 cells were grown in DMEM without phenol red supplemented with 5% FCS treated with dextran-coated charcoal (DCC-FCS), 4.5 g/l D-glucose, non-essential amino acids (100 Amol/l each), 100 units/ml penicillin, 100 Ag/ml streptomycin and 2 mmol/l glutamine at 37°C in a 5% CO_2 atmosphere.

Plasmids. pcDNA3.1/His-Myc-TLR9 was constructed as described (11). Human pSG5-ERα (12) and the 3xERE-TATA-Luc reporter construct (13) were generous gifts from Ingemar Pongratz (Karolinska Institute).

Luciferase reporter activity assays. 3xERE-TATA-Luc reporter construct was used to measure ERα-mediated transcriptional activity. Cells were seeded at $5x10^4$ cells/well in 24-well plates 16 h prior to transfection. Each well was then thansfected with 3xERE-TATA-Luc plasmid and pGL-TK control construct using Lipofectamine reagent (Invitrogen). Luciferase activity was measured on a Monolight luminometer using the dual luciferase reporter assay kit (Promega, Madison). The experiments were performed three times in triplicate. The Student's t-test was used to determine the statistical differences between various experimental and control groups. P<0.05 was considered significant. Shown are means ± SD.

RNA isolation and real-time PCR. Cells were grown for 48 h in phenol red-free DMEM supplemented with 5% DCC-FCS serum and treated with 17ß-estradiol and CpG oligonucleotides at indicated concentration. RNA was collected with TRIzol (Invitrogen), as previously described (14). cDNA was synthesized with 1 μg of total RNA using first-strand cDNA synthesis kit-ReverTra Ace-α (Toyobo) at 99°C and 42°C for 5 and 20 min, respectively. Quantitation of inducible expression of pS2 and PR was performed using SYBR master mix (Toyobo) on an iCycler fitted with an optical assembly unit (Bio-Rad). The relative concentration of pS2 and PR mRNA was calculated, as previously described (15).

TLR9 RNA interference assay. For stable silencing TLR9 in T47D cells, the cells were transfected with TLR9-RNAi or Neo plasmid using Lipofectamine reagent, as described previously (16). Forty-eight hours after transfection, cells were subcloned onto 96-well plates using the limiting dilution method and single-cell clones were established. Down-regulation of TLR9 was verified with Western blotting using anti-TLR9 antibodies (Cell Signaling).

Chromatin immunoprecipitation. The protocol was performed, as previously described (17). Briefly, T47D cells were grown for 48 h in phenol red-free DMEM supplemented with 5% DCC-FCS. Cells were then treated with 17ß-estradiol and CpG oligonucleotides for indicated times, lysized and sonicated,

as previously described. Chromatin fractions were immuno-precipitated with 1 μg of ERα, MC-20 (Sant Cruz Biotechnology) antibody, and the immune complexes were recovered using protein A/G Sepharose (Calbiochem) and processed, as described. The immunoprecipitated DNA was amplified by real-time PCR. The promoter-specific primers of pS2 and PR have been described (15).

Western blot analysis. A BCA protein assay reagent kit (Pierce) was used to measure protein concentration. Samples containing equal amounts of protein were prepared, separated by 12% SDS-PAGE and transferred to Protran nitrocellulose membranes. The blots were probed with antibodies specific for TLR9 (Cell Signaling), and anti-phospho-NF-κB p65 (S536) (Ozyme), with appropriate horseradish peroxidase-conjugated antibodies as secondary antibodies (Cell Signaling). Super-signal West Femto Maximum Sensitivity substrate (Pierce) was used for the chemiluminescent visualization of membrane-bound proteins. The same blots were stripped and reblotted, using anti-actin antibody (Sigma), to show equal loading.

Stable transfection of TLR9 into MCF-7 breast cancer cells. The pcDNA3.1/His-Myc-TLR9 and Neo plasmid were stably transfected into the MCF-7 cells using Lipofectamine reagent (Invitrogen) for 48 h. The cells were then screened under 0.8 mg/ml G418 (Merck, Darmstadt, Germany) for 3 weeks. MCF-7 overexpressing TLR9 was subcloned as MCF-7-TLR9. The expression of TLR9 was verified by Western blot analysis with anti-TLR9 antibody (Cell Signaling).

BrdU incorporation assay. The protocol was performed, as previously described (18). Briefly, T47D or MCF-7 cells were seeded in the absence of E2 for 48 h and then stimulated with 10 nM 17ß-estradiol combined with 10 μM CpG oligonucleotides for 24 h. BrdU (Calbiochem) at a final concentration of 10 μmol/l was added 2 h prior to harvesting. Then cells were fixed, permealized, incubated with FITC-conjugated antibody and subjected to fluorescence-activated cell sorting (FACS) analysis.

Statistical analysis. The results are given as mean ± SD. Student's t-test was used to calculate differences between the various study groups. The difference was considered statistically significant at P<0.05.

Results

TLR9 agonist inhibits ERα-induced ERE transcriptional activity. ERα-mediated transcriptional activity is the most important mechanism by which estrogen exerts its carcino-genetic effect (19). To investigate the effect of TLR9 ligation on ERα-mediated signal pathway, we firstly examined TLR9 expression in two estrogen responsive breast cancer cell lines, T47D and MCF-7 cells. As shown in Fig. 1A, we found that TLR9 was abundant in T47D cells but only mildly expressed in MCF-7 cells. In order to study the effect of TLR9 ligation on ERα-mediated signal pathway, T47D cells were grown in phenol red-free DMEM with 5% DCC-FCS for two days and then treated with 17ß-estradiol in combination with CpG

Figure 1. CpG oligonucleotides inhibit ERα-induced transactivation of breast cancer cells. (A) Western blot analysis of TLR9 expression in the estrogen-dependent breast cancer cell lines T47D and MCF-7. (B) ERE-luciferase reporter gene analysis of ERα-mediated transactivation in T47D cells. T47D cells were cultured in the absence of E2 for 48 h, treated with E2 (10 nM/l) and CpG oligonucleotides (10 μM/l) for 24 h and reporter gene assay was done as described in Materials and methods. (C and D) Real-time PCR analysis of E2 induced pS2 and PR expression in T47D cells, respectively. T47D cells were cultured in the absence of E2 for 48 h and treated with E2 (10 nM/l) and CpG oligonucleotides (10 μM/l) for indicated time. Then real-time PCR was used to quantify mRNA of pS2 and PR as described in Materials and methods. Columns, mean; bars, SD. Representative results of three independent experiments and data were obtained from triplicate experiments. *P<0.05, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

oligonucleotides. The result of ERE-specific reporter gene assay (Fig. 1B) indicates that CpG oligonucleotides significantly suppressed ERα-mediated transcription. Furthermore, we measured two endogenous target genes transcriptionally activated by ERα with real-time PCR. We found that both pS2 and PR were significantly down-regulated due to TLR9 ligation (Fig. 1C and D). In addition, to confirm that the effect of CpG oligonucleotides on ERα-mediated transactivation was exactly triggered by TLR9 activation, we established a subclone of T47D cells, of which the TLR9 expression was effectively silenced as shown by Western blot analysis (Fig. 2A). In this subclone of T47D cells, we found that CpG stimulation failed to yield significant effect on ERα-mediated transactivation, which validates the indispensable involvement of TLR9 in the inhibition of ERα-mediated transactivation by CpG oligonucleotides (Fig. 2B). These results demonstrate that TLR9 agonist CpG oligonucleotides can inhibit ERα-induced transactivation.

TLR9 agonist inhibits recruitment of ERα to estrogen-responsive promoter. To disclose the mechanism of the inhibitory effect of TLR9 agonist on ERα-mediated transactivation, we examined the amount of ERα recruited to estrogen-responsive promoter of pS2 and PR with chromatin immunoprecipitation. We found that 17ß-estradiol alone resulted in a dramatic increase of ERα binding with estrogen responsive promoter. When added together with CpG oligo-nucleotides, ERα bound to the estrogen-responsive promoter

of pS2 and PR were significantly decreased (Fig. 3A and B). Those results imply that the inhibitory effect of CpG oligo-nucleotides on ERα-mediated transactivation may proceeds through suppressing the binding of ERα with its responsive promoter sequences.

TLR9 agonist down-regulates ERα-mediated transactivation by activating NF-κB. To further clarify the mechanism underlying reduced amount of ERα recruited to estrogen responsive promoter on TLR9 ligation, we examined the effect of CpG oligonucleotides on total amount of ERα. However, we did not observe any effect of CpG oligonucleotides on ERα protein level (data not shown). Because it has been determined that there might be a reciprocal antagonism between NF-κB and ERα (20), we used BAY 11-7082, a specific inhibitor of NF-κB by inhibiting I-κBα activation, to test whether the effect of TLR9 agonist on ERα-induced transactivation was caused by activating NF-κB. We found that CpG oligonucleotides was capable of activating NF-κB within 30 min and BAY 11-7082 could almost completely block the activation of NF-κB (Fig. 4A). More importantly, we found that BAY 11-7082 could abolished the inhibitory effect of CpG oligonucleotides on ERα-mediated transactivation (Fig. 4B). These data suggest that inhibition of TLR9 agonist on ERα-mediated trans-activation may be associated with NF-κB activation.

Inhibitory effect of TLR9 agonist on ERα-mediated trans-activation is not restricted to T47D cells. Because TLR9 was

A

T47D

B

Figure 2. Silencing of TLR9 reverses CpG-mediated inhibition on ERα-induced transactivation of breast cancer cells. (A) Western blot analysis to verify the silence of TLR9 expression in T47D cells. (B) ERE-luciferase reporter gene analysis of ERα-mediated transactivation in T47D cells after TLR9 was silenced. Subclone of T47D cells lacking the TLR9 expression were cultured in the absence of E2 for 48 h, treated with E2 (10 nM/l) and CpG oligonucleotides (10 μM/l) for 24 h and reporter gene assay was done as described in Materials and methods. Columns, mean; bars, SD. The data were obtained from triplicate experiments. *P<0.05, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

only mildly expressed in MCF-7 cells, we first established an MCF-7 subclone stably overexpressing TLR9 as indicated by Western blot analysis (Fig. 5A). Then we examined the effect of TLR9 ligation on ERα-mediated transcriptional activity. We found that consistent with the result of T47D cells, CpG oligonucleotides significantly inhibited ERα-mediated transactivity in MCF-7 cells (Fig. 5B). Once NF-κB activity was blocked with BAY 11-7082, no more significant difference of ERα-mediated transactivation was seen between MCF-7 cells treated with E2 in combination with CpG oligo-nucleotides and those treated with E2 alone (Fig. 5B). Thus, consistent with the results of T47D cells, TLR9 agonist could also inhibit ERα-mediated transactivation in another breast cancer cell line MCF-7 by activating NF-κB.

TLR9 agonist inhibits E2-induced proliferation of breast cancer cells. To evaluate the biological significance of TLR9 for breast cancer as a consequence of inhibiting ERα-mediated transactivation, we finally examined the effect of TLR9 agonist on E2-induced proliferation of breast cancer cells using BrdU incorporation assay. We found that the relative proportion of proliferative cells were significantly decreased in T47D cells treated with E2 and CpG oligonucleotides compared with E2 alone (Fig. 6A). For MCF-7 cells, though the mean

A

B

Figure 3. CpG oligonucleotides inhibit recruiting of ERα to estrogen-responsive promoter. (A) T47D cells were cultured in the absence of E2 for 48 h and treated with E2 (10 nM) and CpG oligonucleotides (10 μM/l) for indicated time. ChIP was done as described in Materials and methods. The precipitated DNA was subject to real-time PCR to quantify the amount of pS2 promoter sequence pulled down by ERα in ChIP. (B) or PR promoter sequence pulled down by ERα with ChIP was quantified. Columns, mean; bars, SD. The data were obtained from triplicate experiments. *P<0.05, **P<0.01, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

A

B

Figure 4. Effect of TLR9 agonist on ERα-mediated transactivation is dependent on NF-κB activation. (A) Western blot analysis of the inhibitory efficiency of BAY 11-7082 on CpG-induced activation of NF-κB. T47D cells were cultured in the absence of E2 for 48 h, pretreated with 20 μM/l BAY 11-7082 for 30 min and stimulated with E2 (10 nM) and CpG oligonucleotides (10 μM/l) for indicated time. Western blot analysis was done as described in Materials and methods using anti-phospho-p65 (S536) antibodies. (B) Report gene analysis of the association between NF-κB activation and CpG-mediated inhibition of ERα-induced transactivation. T47D cells were cultured in the absence of E2 for 48 h. Specific NF-κB inhibitor BAY 11-7082 was added 30 min prior to treatment of E2 (10 nM) and CpG oligonucleotides (10 μM/l) for 24 h. Reporter gene assay was done as described in Materials and methods. Columns, mean; bars, SD. The data were obtained from triplicate experiments. *P<0.05, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

Figure 5. CpG oligonucleotides inhibit ERα-mediated transactivation in MCF-7 cells. (A) Western blot analysis of expression efficiency of stably transfected pcDNA3.1-TLR9 in MCF-7 cells. (B) Reporter gene analysis of the effect of BAY 11-7082 on CpG-mediated inhibition of ERα-mediated transactivation. MCF-7 cells were transfected with the reporter gene constructs and cultured in the absence of E2 for 48 h. BAY 11-7082 (20 μM/l) was added 30 min before stimulation with E2 (10 nM/l) and CpG oligonucleotides (10 μM/l) for 24 h. Reporter gene assay was done as described in Materials and methods. Columns, mean; bars, SD. The data were obtained from triplicate experiments. *P<0.05, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

proliferative percent of cells in CpG group was lower than non-CpG control, the difference is not statistically significant. However, the proliferation ability was significantly decreased in all subclones of MCF-7 cells forced to overexpress TLR9. It seems that the inhibition of CpG on E2-induced proliferation

is proportionate to the over-expression level of TLR9 in MCF-7 cells (Fig. 6B and C). This result suggests that TLR9 ligation may negatively regulate the proliferation of breast cancer in response to estrogen.

Discussion

Infection and the resulting inflammation, are important regulators of tumor progression (21). For example, chemo-kines and cytokines derived from the immune and inflam-matory cells can dramatically affect cancer cell behavior by shaping the host microenvironment. Since TLR9 was recognized as the receptor for unmethylated CpG DNA of most bacteria and DNA viruses, many TLR9-based approaches have been reported to enhance anti-tumor immunity, some of which have even entered Phase III trials (22). However, the direct effect of TLR9 on tumor cells largely remains unkown. Our study, for the first time, investigated the effect of TLR9 on estrogen responsiveness of breast cancer.

Using two estrogen responsive breast cancer cell lines as a model, we found that TLR9 may act as a negative regulator in ERα-mediated transactivity. We pinned down the molecular mechanism of that effect to the downstream NF-κB activation of TLR9 signal pathway. Consequently we also observed that TLR9 activation may suppress E2-induced proliferation of breast cancer cells.

CpG binds to the TLR9 that resides in the endoplasmic reticulum and recruits MyD88 to initiate signaling (23-25). Adaptor recruitment is followed by phosphorylation of members of IL-1R-associated kinase (IRAK) family and TNFR-associated factor 6 (TRAF6), which further leads to the activation of NF-κB, the major endpoint of the TLR9


Figure 6. CpG oligonucleotides inhibit E2-induced proliferation of breast cancer cells. (A) BrdU incorporation analysis of the effect of TLR9 ligation on E2-induced proliferation of T47D cells. T47D cells were cultured in the absence of E2 for 48 h and treated with E2 (10 nM/l) and CpG oligonucleotides (10 μM/l) for another 24 h. BrdU incorporation assay was done as described in Materials and methods. (B) BrdU incorporation analysis of the effect of TLR9 ligation on E2-induced proliferation of MCF-7 cells. Wild-type MCF-7 cells and another three subclones of MCF-7 cells overexpressing TLR9 were treated in the same way as T47D cells. (C) Western blot analysis of TLR9 protein in all the MCF-7 subclones. WT, wild-type MCF-7 cells; M1-3: different stable subclones of MCF-7 cells overexpressing TLR9. Columns, mean; bars, SD. The data were obtained from triplicate experiments. *P<0.05, significant difference between samples treated with unstimulatory CpG control (non-CpG, white columns) and CpG oligonucleotides (CpG, black columns).

signaling (26). The activation of I-κBα and its degradation thereafter is an indispensable step for NF-κB activation (27), so we used BAY 11-7082, an inhibitor of I-κBα phosphorylation, to block TLR9-induced NF-κB activation and determined that NF-κB activation is essential in TLR9-mediated negative regulation of estrogen responsiveness of breast cancer cells. In support of our observation, many studies have demonstrated that there might exist a reciprocal antagonism between ERα-mediated signaling pathway and NF-κB activity (20,28-31). This interaction is believed to take place by direct protein-protein interactions (30-32), inhibition of DNA binding (33,34), induction of IκB expression (35), or coactivator sharing (28,29). As a transcriptional nuclear factor activated directly by binding with E2, ERα is the major receptor for estrogen in estrogen-induced carcinogenesis of breast cancer. Our study indicates that TLR9, by activating NF-κB, might negatively regulate ERα-induced transactivation of breast cancer, which provides a novel biological example of the antagonism between NF-κB and ERα. Actually, we speculate that ERα transactivation also likely inhibits the expression of NF-κB regulated genes. So the extent of stimulation of both the ERα and TLR9 (or other TLRs that activate NF-κB) pathway is important for the final biological response. The balance between both pathway is important and the resulting gene expression profile determines whether cells proliferate, are capable of invasion or undergo apoptosis.

Apart from its adjuvant effect in tumor immunotherapy, TLR9 agonist was also recently found to promote tumor invasion in breast cancer, glioblastoma and prostate cancer (10,36). Given the higher expression of TLR9 in invasive breast cancer cells, we speculate that TLR9 may have different biological effect during the different phases of breast cancer development. Not until estrogen-independent stage, might breast cancer evolve to fully up-regulate TLR9 expression and utilize its invasive effect due to its negative effect on estrogen responsiveness of breast cancer at the early hormone-dependent stage according to our study. Or as a multifunctional molecule, the final effect of TLR9 may vary according to specific cellular context. Actually, it has been observed that incubation of breast cancer cells with CpG leads to a decreased viability (10), which is consistent with our data gained with a different method to measure viable cell number. This adds new evidence to our conclusions that TLR9 might be a novel mechanism in negatively regulating ERα-mediated transactivation of breast cancer, which needs to be further confirmed in primary cancer cells.

In summary, our finding is the first to suggest that TLR9 activation may suppress ERα-mediated transactivation of breast cancer by activating NF-κB. Although the detailed mechanism of this regulation on estrogen responsiveness still needs further exploration, our study implies that TLR9 has its own biologically regulatory effect apart from its adjuvant role in immunotherapy. Considering its direct inhibitory effect on breast cancer and adjuvant effect in tumor immunotherapy, TLR9 may have the potential in the treatment of hormone-related cancers.

Acknowledgements

References

1. Akira S and Hemmi H: Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 85: 85-95, 2003.
2. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ and Segal DM: TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol 173: 1179-1183, 2004.
3. Wagner H: The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381-386, 2004.
4. Evans RM: The steroid and thyroid hormone receptor superfamily. Science 240: 889-895, 1998.
5. Persson IJ: Estrogens in the causation of breast, endometrial and ovarian cancers - evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74: 357-364, 2002.
6. Tsai MJ and O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63: 451-486, 1994.
7. Yue W, Wang JP, Li Y, Bocchinfuso WP, Korach KS, Devanesan PD, Rogan E, Cavalieri E and Santen RJ: Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res 11: 925s-930s, 2005.
8. Chan S: A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. Semin Oncol 29: 129-133, 2006.
9. Zaks-Zilberman M, Zaks TZ and Vogel SN: Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine15: 156-165, 2001.
10. Merrell MA, Ilvesaro JM, Lehtonen N, *et al*: Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 4: 437-447, 2006.
11. Zhou R, Norton JE, Zhang N and Dean DA: Electroporation-mediated transfer of plasmids to the lung results in reduced TLR9 signaling and inflammation. Gene Ther 14: 775-780, 2007.
12. Brunnberg S, Pettersson K, Rydin E, Matthews J, Hanberg A and Pongratz I: The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc Natl Acad Sci USA 100: 6517-6522, 2003.
13. Delaunay F, Pettersson K, Tujague M and Gustafsson JA: Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58: 584-590, 2000.
14. Sun H, Li N, Wang X, *et al*: Molecular cloning and character-ization of a novel cystatin-like molecule, CLM, from human bone marrow stromal cells. Biochem Biophys Res Commun 301: 176-182, 2003.
15. Fan M, Nakshatri H and Nephew KP: Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation. Mol Endocrinol 18: 2603-2615, 2004.
16. Ilvesaro JM, Merrell MA, Li L, *et al*: Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol Cancer Res 6: 1534-1543, 2008.
17. Matthews J, Wihlén B, Tujague M, Wan J, Ström A and Gustafsson JA: Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20: 534-543, 2006.
18. Peng X, Mehta R, Wang S, Chellappan S and Mehta RG: Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res 66: 7361-7369, 2006.
19. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
20. Evans MJ, Eckert A, Lai K, Adelman SJ and Harnish DC: Reciprocal antagonism between estrogen receptor and NF-κB activity in vivo. Circ Res 89: 823-830, 2001.
21. Coussens LM and Werb Z: Inflammation and cancer. Nature 420: 860-867, 2002.
22. Krieg AM: Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471-484, 2006.

i H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, moto M, Hoshino K, Wagner H, Takeda K and Akira S: A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.

24. Medzhitov R: Toll-like receptors and innate immunity. Nat Rev Immunol 1: 135-145, 2001.

25. Latz, E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T and Golenbock DT: TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198, 2004.

26. Dunne A and O'Neill LA: The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE re3, 2003.

27. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 18: 621-623, 2000.

28. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR and Karathanasis SK: The role of CBP in estrogen receptor cross-talk with nuclear factorkappaB in HepG2 cells. Endocrinology 141: 3403-3411, 2000.

29. Speir E, Yu ZX, Takeda K, Ferrans VJ and Cannon RO: Competition for p300 regulates transcription by estrogen receptors and nuclear factorkappaB in human coronary smooth muscle cells. Circ Res 87: 1006-1011, 2000.

30. Ray A and Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci USA 91: 752-756, 1994.

31. Quaedackers ME, van den Brink CE, van der Saag PT and Tertoolen LG: Direct interaction between estrogen receptor α and NF-κB in the nucleus of living cells. Mol Cell Endocrinol 273: 42-50, 2007.

32. Stein B and Yang MX: Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Mol Cell Biol 15: 4971-4979, 1995.

33. Deshpande R, Khalili H, Pergolizzi RG, Michael SD and Chang MD: Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am J Reprod Immunol 38: 46-54, 1997.

34. Ray P, Ghosh SK, Zhang DH and Ray A: Repression of interleukin-6 gene expression by 17ß-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-kappa B by the estrogen receptor. FEBS Lett 409: 79-85, 1997.

35. Sun WH, Keller ET, Stebler BS and Ershler WB: Estrogen inhibits phorbol ester-induced I kappa B alpha transcription and protein degradation. Biochem Biophys Res Commun 244: 691-695, 1998.

36. Ilvesaro JM, Merrell MA, Swain TM, Davidson J, Zayzafoon M, Harris KW and Selander KS: Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 67: 774-781, 2007.